Tehran University of Medical Sciences

Science Communicator Platform

Share By
Mitochondria Determine Response to Anti-Programmed Cell Death Protein-1 (Anti-Pd-1) Immunotherapy: An Evidence-Based Hypothesis Publisher Pubmed



Akbari H1, 2 ; Taghizadehhesary F3 ; Bahadori M4
Authors

Source: Mitochondrion Published:2022


Abstract

Immunotherapy based on programmed cell death protein-1 (PD-1) is a promising approach in oncology. However, a significant fraction of patients remain unresponsive. Therefore, it is imperative to clarify the relevant predictive factors. A decrease in cellular adenosine triphosphate (c-ATP) level can predispose to cellular dysfunction. ATP is a prerequisite for proper T cell migration and activation. Therefore, a decrease in the c-ATP level impairs T cell function and promotes cancer progression. This article gives an overview of the potential predictive factors of PD-1 blockade. Besides, it highlights the pivotal role of mitochondria in response to anti-PD-1 therapies. © 2021 Elsevier B.V. and Mitochondria Research Society
Other Related Docs
6. Tumor Immunology, Clinical Immunology (2022)
13. Cancer Immunotherapy, Interdisciplinary Biotechnological Advances (2025)
18. Biomarkers for Immune Checkpoint Inhibitors, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
20. How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer, International Immunopharmacology (2020)